We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Urinary Epidermal Growth Factor Investigated for Diabetes Nephropathy

By LabMedica International staff writers
Posted on 06 Aug 2021
Print article
The Invitrogen Human EGF ELISA Kit measures levels of epidermal growth factor (EGF) in human serum, plasma, and cell culture supernatant using 96-well plates (Photo courtesy of Thermo Fisher Scientific)
The Invitrogen Human EGF ELISA Kit measures levels of epidermal growth factor (EGF) in human serum, plasma, and cell culture supernatant using 96-well plates (Photo courtesy of Thermo Fisher Scientific)
Type 1 diabetes mellitus is an auto-immune metabolic disease with chronic hyperglycemia. For many patients with type 1 diabetes (T1DM), it is challenging to maintain near-normal glucose blood levels and to reduce the risk of both acute (hypoglycemia, ketoacidosis) and chronic microvascular (retinopathy, neuropathy and nephropathy) and macrovascular complications.

Epidermal growth factor (EGF) stimulates cell growth, proliferation and differentiation by binding to its receptor EGFR. In the kidney, EGF is involved in the repairing process of kidney structures. EGF is synthetized along the kidney tubules and excreted into the urine, making urinary EGF a potential hallmark for regenerative functional capacity of the tubulointerstitial compartment of the kidney.

Pediatric Nephrologists at the University of Antwerp (Antwerp, Belgium) and their colleagues included in a study 158 children with type 1 diabetes mellitus and 40 healthy controls. Serum and urine samples were collected three times with an interval of at least one month to determine creatinine (serum and urine), epidermal growth factor and albumin (urine).

The team explored whether urinary epidermal growth factor (uEGF) might serve as an early marker of diabetes nephropathy compared to microalbuminuria in children and adolescents. Urinary EGF was measured using an EGF human Elisa kit (Invitrogen, Waltham, MA, USA). The detection limit of this assay was 3.9 pg/mL. For the comparative analysis in children and adolescents, the scientists corrected the values accounting for growth. Serum and urine creatinine, urine total protein and microalbuminuria were analyzed with the Dimension Vista system (Siemens Healthcare Diagnostics, Deerfield, MA, USA).

The investigators reported that urinary EGF was significantly lower in T1DM compared to healthy children. In children with T1DM, the mean duration of diabetes was 5.49 ± 3.29 years with a mean HbA1c of 7.7 ± 1.0% (60 ± 11 mmol/mol) and a mean insulin need of 0.87 ± 0.20 units/kg/day. Forty-four children (27.8%) were younger than six years when T1DM was diagnosed. A relatively lower glomerular filtration rate (eGFR) was associated with a decreased uEGF. The uEGF was independently associated with eGFR in a multivariate analysis. None of the patients with an eGFR < 90 mL/min/1.73 m2 had microalbuminuria > 30 mg/g creatinine, while 9.5% and 10.1% of the patients with an eGFR 90–110 mL/min/1.73 m2 and > 110 mL/min/1.73 m2 respectively did have microalbuminuria > 30 mg/g creatinine.

The authors concluded that uEGF is a promising ‘next generation’ biomarker associated with early signs of diabetes nephropathy in children and adolescents and worth further investigation as a single biomarker or as one of a multi-biomarker panel. The study was published on July 7, 2021 in the journal Diabetes Research and Clinical Practice.

Related Links:

University of Antwerp
Invitrogen
Siemens Healthcare Diagnostics 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Coagulation Analyzer
CS-2400

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.